Skip to search formSkip to main contentSkip to account menu

duvelisib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Phosphoinositide 3-kinases (PI3Ks) are a family of ubiquitously distributed lipid kinases that control a wide variety of… 
2019
2019
Introduction: Duvelisib (DUV), an oral inhibitor of PI3K-δ/γ, and venetoclax (VEN), an oral inhibitor of BCL-2, are both… 
2018
2018
Epstein–Barr virus (EBV) is a ubiquitous oncogenic virus that is associated with B cell lymphomas, including Burkitt lymphoma and… 
2017
2017
37.5% with 4 CRs (25%) in ABC patient. Response to copanlisib was 25% in pts with (2/8) and without (8/32) CD79B mutations. Five… 
2016
2016
Background: Mantle cell lymphoma (MCL) is an incurable subtype of B-cell lymphoma. Ibrutinib, a first-in-class, once-daily, oral… 
2015
2015
Background: Duvelisib, a potent inhibitor of the δ and γ isoforms of phosphoinositide-3-kinase (PI3K) is being developed as a… 
2015
2015
Background: FCR remains the gold standard for the initial treatment of younger patients with CLL, yet only about 20% of patients… 
2015
2015
8559 Background: Signaling via PI3K-δ and PI3K-γ has distinct and complementary effects on the tumor cell/ tumor microenvironment… 
2014
2014
Introduction: Peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) are uncommon lymphoid malignancies. Approved…